Business Update Neutral

2026-11-07 17:40

- Divi's Laboratories Ltd informed the stock exchanges about the availability of the audio recording for the Q2 FY27 earnings conference call. - The call was held on November 07, 2026, at 14:00 hrs IST. - The audio recording has been made accessible on the company's website under the Investor Relations section.

Financials Positive

2026-11-07 12:14

Q2 FY27 Consolidated Revenue ₹3,676Cr vs ₹2,715Cr (▲35% YoY) EBITDA ₹1,566Cr vs ₹888Cr (▲76% YoY) PAT ₹1,127Cr vs ₹689Cr (▲64% YoY) EBITDA Margin 42.6% vs 32.7% (▲990bps)

Financials Positive

2026-11-07 12:02

Q2 FY27 Consolidated Revenue ₹3,676Cr vs ₹2,715Cr (▲35% YoY) EBITDA ₹1,566Cr vs ₹888Cr (▲76% YoY) PAT ₹1,127Cr vs ₹689Cr (▲64% YoY) EBITDA Margin 42.6% vs 32.7% (▲990bps)

Financials Neutral

2026-11-07 11:57

Q2 FY27 Consolidated Revenue ₹3,676Cr vs ₹2,715Cr (▲35% YoY) EBITDA ₹1,566Cr vs ₹888Cr (▲76% YoY) PAT ₹1,127Cr vs ₹689Cr (▲64% YoY) EBITDA Margin 42.6% vs 32.7% (▲989bps)

Business Update Neutral

2026-11-02 08:59

Concall Schedule Concall Date: November 07, 2026 Concall Time: 14:00 hrs (IST)

Governance Neutral

2026-10-22 16:59

- Board meeting scheduled on Saturday, November 07, 2026. - To consider and approve unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026. - Trading window remains closed until November 09, 2026.

Governance Positive

2026-08-10 19:33

- The 36th Annual General Meeting (AGM) was held on August 10, 2026; all resolutions passed with requisite majority. - A dividend of ₹30 per equity share (1,500%) for FY26 was recommended. - The company reported FY26 consolidated total income of ₹11,067 Cr (▲13.95% YoY) and Q1 FY27 consolidated income of ₹3,144 Cr.

Governance Positive

2026-08-10 19:26

- The 36th Annual General Meeting was held on August 10, 2026, where all resolutions were passed with requisite majority. - A dividend of ₹30 per equity share (1500%) for the financial year ended March 31, 2026, was declared. - For FY26, Consolidated Total Income increased to ₹11,067 crores (vs ₹9,712 crores in previous year), and Profit After Tax (PAT) stood at ₹2,568 crores. - For Q1 FY27, Consolidated Total Income was ₹3,144 crores, with Profit After Tax (PAT) of ₹902 crores. - The company highlighted ongoing capacity expansion, advancements in technology, and a positive outlook for the global pharmaceutical and CDMO markets, driven by specialty medicines and peptide therapeutics.

Financials Positive

2026-08-06 14:32

- Consolidated Total Income ₹3,144Cr vs ₹2,529Cr (▲24.3% YoY) - Consolidated PAT ₹902Cr vs ₹545Cr (▲65.5% YoY) - Management stated EBITDA margin was similar to last year. - Custom Synthesis contributed 60% and Generics 40% of revenue in Q1 FY27. - Company maintains double-digit growth outlook for the full financial year.

Financials Positive

2026-08-06 14:27

- Consolidated Total Income ₹3,144 Cr vs ₹2,529 Cr (▲24.3% YoY) - Consolidated PBT ₹1,180 Cr vs ₹733 Cr (▲61.0% YoY) - Consolidated PAT ₹902 Cr vs ₹545 Cr (▲65.5% YoY) - Management expects double-digit growth for the full year FY27. - Custom Synthesis contributed 60% and Generics 40% to revenue.

Business Update Neutral

2026-08-01 15:54

- Audio recording of Q1 FY27 earnings conference call held on August 01, 2026, at 14:00 Hrs. (IST) for the quarter ended June 30, 2026. - The recording has been uploaded on Divi's Laboratories Limited website under the Investors relations section.

Business Update Neutral

2026-08-01 15:46

- Audio recording of Q1 FY27 earnings conference call for the quarter ended June 30, 2026, held on August 01, 2026, has been uploaded on the company's website.

Financials Positive

2026-08-01 11:44

- Consolidated Revenue ₹3,080 Cr vs ₹2,410 Cr (▲27.8% YoY) - EBITDA ₹1,255 Cr vs ₹729 Cr (▲72.2% YoY) - PAT ₹902 Cr vs ₹545 Cr (▲65.5% YoY) - EBITDA Margin 40.75% vs 30.25% (▲1050bps)

Financials Positive

2026-08-01 11:40

- Consolidated Revenue ₹3080Cr vs ₹2410Cr (▲28% YoY) - EBITDA ₹1255Cr vs ₹729Cr (▲72% YoY) - PAT ₹902Cr vs ₹545Cr (▲66% YoY) - EBITDA Margin 41% vs 30% (▲1050bps)

Financials Positive

2026-08-01 11:37

- Consolidated Revenue ₹3080Cr vs ₹2410Cr (▲28% YoY) - EBITDA ₹1255Cr vs ₹729Cr (▲72% YoY) - PAT ₹902Cr vs ₹545Cr (▲66% YoY) - EBITDA Margin 40.8% vs 30.3% (▲1050bps) - Mr. B. Vara Prasad and Mr. J. Srinivasa Rao appointed as Senior Management Personnel (General Managers for Engineering Purchase and Raw Materials Purchase respectively) effective August 01, 2026.

Financials Positive

2026-08-01 11:34

- Consolidated Revenue ₹3,080 Cr vs ₹2,410 Cr (▲27.8% YoY) - EBITDA ₹1,255 Cr vs ₹729 Cr (▲72.2% YoY) - PAT ₹902 Cr vs ₹545 Cr (▲65.5% YoY) - EBITDA Margin 40.75% vs 30.25% (▲1050bps)

Governance Neutral

2026-07-31 09:15

- Divi's Laboratories Limited announced the cessation of Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), as Senior Management Personnel. - Their cessation is effective from the close of business hours on July 31, 2026, due to retirement.

Governance Neutral

2026-07-31 09:13

- Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), will retire from the company. - They will cease to be Senior Management Personnel effective from July 31, 2026.

Business Update Neutral

2026-07-24 10:33

- Concall Schedule - Concall Date: August 01, 2026 - Concall Time: 14:00 hrs (IST)

Business Update Neutral

2026-07-24 10:30

- Concall Schedule - Concall Date: August 01, 2026 - Concall Time: 14:00 hrs (IST)

Financials Neutral

2026-07-20 09:00

- Board meeting scheduled for August 01, 2026. - Purpose: To consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. - Trading window to remain closed till August 03, 2026.

Governance Positive

2026-07-15 17:46

- The 36th Annual General Meeting (AGM) will be held on August 10, 2026, at 10:00 a.m. IST via Video Conferencing. - The Board recommended a dividend of ₹30/- per equity share (1,500%) for FY2025-26. - The Record Date for dividend is July 24, 2026, with payment on/from August 14, 2026. - Agenda includes adoption of financial statements and re-appointment of directors.

Business Update Positive

2026-07-15 17:42

- Filed Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - Reported ~13,500 TCO₂e GHG emissions reduced and ~1,59,500 KL water conserved. - Committed to net-zero GHG emissions by FY 2050 with specific environmental and safety targets. No regulatory issues.

Governance Positive

2026-07-15 17:34

- Notice of 36th Annual General Meeting (AGM) on August 10, 2026, at 10:00 a.m. IST via VC/OAVM. - Agenda includes adoption of FY2025-26 financials and declaration of ₹30/- per share dividend. - Record date for dividend: July 24, 2026. Payment from August 14, 2026. E-voting: August 06-09, 2026.

Governance Neutral

2026-07-15 14:50

- 36th Annual General Meeting (AGM) of the Company is scheduled for Monday, August 10, 2026, at 10:00 a.m. (IST) via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). - E-voting will commence on Thursday, August 06, 2026, at 9:00 a.m. (IST) and conclude on Sunday, August 09, 2026, at 5:00 p.m. (IST). - The Annual Report for the financial year 2025-26 has been made available to members and uploaded on the Company's website. - FY 2025-26 Financial Highlights: Total Income ₹10,894 crores, Profit After Tax ₹2,607 crores, Earnings Per Share ₹98.19. - The company invested over ₹15 billion in FY 2025-26 across its manufacturing network.

Routine Neutral

2026-06-30 10:56

- Trading Window for dealing in company securities will close from July 01, 2026. - It will remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - The date of the Board meeting for results will be intimated in due course.

Routine Neutral

2026-06-30 10:54

- Trading Window for dealing in securities will remain closed from July 01, 2026. - Closure is till 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - Date of Board meeting for results will be intimated in due course.

Financials Positive

2026-06-11 09:12

- Divi's Laboratories declared a dividend of ₹30 per share (1500%) for FY 2025-26. - Record date for dividend: July 24, 2026. - Dividend payment will be on or after August 14, 2026, post AGM approval on August 10, 2026. - Information shared regarding Income Tax deduction at source (TDS) on dividend.

Routine Neutral

2026-06-11 09:09

- Divi's Labs issued communication on TDS for FY25-26 dividend. - Board recommended ₹30/share (1500%) dividend on May 23, 2026. - Record date: July 24, 2026. Payment after August 10, 2026, AGM approval. - Shareholders must submit tax documents by July 24, 2026.

Business Update Positive

2026-05-29 10:37

Divi's Laboratories reiterated its commitment to achieving double-digit revenue growth and anticipates stable EBITDA margins despite facing competitive pricing pressures and increased raw material and freight costs. The company reported capital work in progress of ₹2,113 crores and FY26 Capex of ₹2,500 crores, with a steady capex plan for FY27 unless new major custom synthesis projects emerge. Growth is expected from healthy volume expansion in generics, a robust pipeline in custom synthesis with projects advancing towards commercialization, and significant investments in the peptide business, where the company aims for global leadership in scale. The management effectively mitigated supply chain and geopolitical disruptions, preventing any revenue loss in Q4 FY26.

Business Update Positive

2026-05-29 10:32

Divi's Laboratories reported strong Q4 and FY26 performance. Management anticipates double-digit revenue growth for the future, with margins expected to remain stable despite competitive pricing and raw material cost pressures. The company capitalized ₹2,500 crores in FY26 (₹800 crores in Q4) and has ₹2,113 crores in capital work in progress, with revenue from capex expected within 2 years. Supply chain disruptions and increased freight costs due to geopolitical tensions were successfully managed, ensuring supply reliability. Growth drivers include a strong project pipeline in custom synthesis, deepening capabilities in peptides with validated fragments, and commercial sales in iodine-based contrast media. Exports constitute 89% of revenue, benefiting from currency depreciation. Divi's aims to be a leading global player in the peptide segment.

Financials Positive

2026-05-25 08:57

Consolidated Revenue ₹2831Cr vs ₹2585Cr (▲10% YoY), EBITDA ₹934Cr vs ₹886Cr (▲5% YoY), PAT ₹751Cr vs ₹662Cr (▲13% YoY). EBITDA Margin 33% vs 34% (▼128bps). The company also recommended a final dividend of ₹30/- per equity share for FY 2025-26.

Financials Positive

2026-05-25 08:47

Divi's Laboratories Limited reported consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹2,831 Cr vs ₹2,585 Cr (▲9.51% YoY). EBITDA was ₹1,089 Cr vs ₹972 Cr (▲11.93% YoY). PAT was ₹751 Cr vs ₹662 Cr (▲13.44% YoY). EBITDA Margin expanded from 37.60% to 38.47% (▲87bps). The company recommended a final dividend of ₹30/- per equity share for FY2025-26, and auditors issued an unmodified opinion.

Business Update Neutral

2026-05-23 18:35

Divi's Laboratories Limited announced the upload of the audio recording of its Q4 FY26 earnings conference call, held on May 23, 2026, for the quarter and year ended March 31, 2026, to the investors relations section of its website.

Business Update Neutral

2026-05-23 18:31

Divi's Laboratories Limited announced the upload of the audio recording for its Q4 FY26 earnings conference call, held on May 23, 2026, at 14:30 Hrs. (IST), to the Investors Relations section of their website.

Financials Positive

2026-05-23 12:58

Consolidated Revenue ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA ₹1,089Cr vs ₹972Cr (▲12.0% YoY), PAT ₹751Cr vs ₹662Cr (▲13.4% YoY). EBITDA Margin 38.5% vs 37.6% (▲90bps). A final dividend of ₹30/- per equity share was recommended for the financial year 2025-26, subject to shareholder approval.

Financials Positive

2026-05-23 12:21

Divi's Laboratories Limited announced its Consolidated Q4 FY2026 results. Consolidated Revenue was ₹2,831Cr vs ₹2,585Cr (▲10% YoY), EBITDA was ₹934Cr vs ₹886Cr (▲5% YoY), and PAT was ₹751Cr vs ₹662Cr (▲13% YoY). EBITDA Margin was 33% vs 34% (▼128bps). The company also recommended a final dividend of ₹30/- per equity share for FY2025-26.

Financials Positive

2026-05-23 12:19

Consolidated Revenue for Q4 FY26 was ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA was ₹934Cr vs ₹886Cr (▲5.4% YoY), and PAT was ₹751Cr vs ₹662Cr (▲13.4% YoY). EBITDA Margin was 33.0% vs 34.3% (▼128bps). The Board also recommended a final dividend of ₹30/- per equity share for FY 2025-26, and the 36th AGM is scheduled for August 10, 2026.

Financials Positive

2026-05-23 12:16

Divi's Laboratories Limited announced its Consolidated Financial Results for Q4 FY26. Consolidated Revenue stood at ₹2,831Cr against ₹2,585Cr (▲9.52% YoY), EBITDA at ₹934Cr against ₹886Cr (▲5.42% YoY), and PAT at ₹751Cr against ₹662Cr (▲13.44% YoY). The EBITDA Margin was 33.0% compared to 34.3% in the prior year quarter (▼130bps). The company also recommended a final dividend of ₹30 per equity share for FY2025-26.

Financials Positive

2026-05-23 12:14

Divi's Laboratories reported Consolidated Revenue of ₹2,831Cr vs ₹2,585Cr (▲9.5% YoY), EBITDA of ₹934Cr vs ₹886Cr (▲5.4% YoY), and PAT of ₹751Cr vs ₹662Cr (▲13.4% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 33.0% vs 34.3% (▼130bps). The Board also recommended a final dividend of ₹30/- per equity share for the financial year 2025-26.

Financials Positive

2026-05-23 12:13

Divi's Laboratories Limited reported Consolidated Revenue of ₹2,831 Cr vs ₹2,585 Cr (▲9.5% YoY), EBITDA of ₹934 Cr vs ₹886 Cr (▲5.4% YoY), and PAT of ₹751 Cr vs ₹662 Cr (▲13.4% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 33.0% vs 34.3% (▼130bps). The Board also recommended a final dividend of ₹30/- per equity share for FY 2025-26.

Financials Neutral

2026-05-15 19:11

Divi's Laboratories Limited announced that its audited financial results for the quarter and year ended March 31, 2026 (Q4FY26), will be released on May 23, 2026. Following the release, the company will host an earnings conference call on the same day at 14:30 hrs (IST) to discuss its financial performance.

Financials Neutral

2026-05-15 19:09

Divi's Laboratories Limited announced an earnings conference call to discuss its audited financial results for the quarter and year ended March 31, 2026 (Q4FY26). The conference call is scheduled for May 23, 2026, at 14:30 hrs (IST).

Financials Neutral

2026-05-14 12:11

Divi's Laboratories Limited announced that its Board of Directors will meet on May 23, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend for the financial year 2025-26. The trading window for dealing in securities of the company will remain closed until May 25, 2026.

Routine Neutral

2026-04-06 15:22

Divi's Laboratories Limited submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026, confirming compliance regarding dematerialization of securities.

Routine Neutral

2026-03-31 10:03

Divi's Laboratories Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ended March 31, 2026. The Board meeting date will be intimated subsequently.

Routine Neutral

2026-03-31 09:59

Divi's Laboratories Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ended March 31, 2026. The date of the Board meeting for results declaration will be intimated in due course.

Business Update Negative

2026-03-21 16:18

CRITICAL RED FLAG DETECTED

Divi's Laboratories received a Draft Order from the Income Tax Authority for FY2022-23, proposing additions/disallowances of ₹570.51 crores related to Transfer Pricing and corporate tax adjustments, potentially leading to additional tax liability and penalty. The company plans to appeal.

Business Update Negative

2026-03-21 16:12

CRITICAL RED FLAG DETECTED

Divi's Laboratories received a Draft Assessment Order for FY2022-23 proposing additions/disallowances of Rs.570.51 crores due to Transfer Pricing and corporate tax adjustments. This implies additional income tax liability and potential penalties for under-reporting. The company plans to appeal.

Business Update Positive

2026-02-14 15:24

Transcript of Divi's Laboratories Limited's Q3FY2026 earnings conference call held on Feb 11, 2026. Highlights included stable Generics performance, progressing Custom Synthesis projects, healthy Nutraceuticals segment, a successfully concluded U.S. FDA inspection, and a one-time ₹74 Cr impact from new labor codes on employee benefits.

Business Update Positive

2026-02-14 15:20

Divi's Laboratories submitted the transcript of its Q3FY2026 earnings conference call for the quarter and nine months ended December 31, 2025. Key updates included stable performance in Generics, healthy performance in Nutraceuticals, and a successful FDA inspection. An exceptional item of ₹74 crore was reported due to new labor codes.

Routine Neutral

2026-02-12 12:52

New Filing detected. See link for details.

Business Update Neutral

2026-02-11 17:33

Divi's Laboratories Limited informed that the audio recording of the Q3FY26 earnings conference call, held on February 11, 2026, for the quarter and nine months ended December 31, 2025, has been uploaded to their website for investor access.

Business Update Neutral

2026-02-11 17:28

Divi's Laboratories Limited announced the audio recording of its Q3FY26 earnings conference call, held on February 11, 2026, for the quarter ended December 31, 2025, has been uploaded on its website.

Routine Neutral

2026-02-11 12:40

New Filing detected. See link for details.

Financials Positive

2026-02-11 12:39

Consolidated Revenue ₹2,604Cr vs ₹2,319Cr (▲12.29% YoY), EBITDA ₹890Cr vs ₹743Cr (▲19.78% YoY), PAT ₹583Cr vs ₹589Cr (▼1.02% YoY). EBITDA Margin 34.18% vs 32.04% (▲214bps). The PAT decline is attributed to a one-time exceptional item of ₹74Cr for labour codes impact.

Financials Neutral

2026-02-03 17:09

Divi's Laboratories Limited announced an earnings conference call on February 11, 2026, at 15:00 hrs (IST) to discuss the unaudited financial results for the quarter and nine months ended December 31, 2025 (Q3FY26).

DIVISLAB

Divi's Laboratories Limited

Price Chart

Filing History

Unlock Full History